رسالة جامعية

Development of Enzyme Replacement and Pharmacological Chaperone Approaches for Therapy of Metachromatic Leukodystrophy

التفاصيل البيبلوغرافية
العنوان: Development of Enzyme Replacement and Pharmacological Chaperone Approaches for Therapy of Metachromatic Leukodystrophy
المؤلفون: Schuster, Tilman
المساهمون: Gieselmann, Volkmar, Burgdorf, Sven
بيانات النشر: Universitäts- und Landesbibliothek Bonn
سنة النشر: 2015
المجموعة: bonndoc - The Repository of the University of Bonn
مصطلحات موضوعية: Lysosomale Speichererkrankungen, Nanopartikel, Blut-Hirn-Schranke, Mannose-6-Phosphat-Rezeptor, Arylsulfatase A, High-Throughput-Screening, Gewebeverteilung, Lysosomal Storage Diseases, Nanoparticles, Blood-Brain Barrier, Mannose 6-phosphate receptor, Tissue distribution, ddc:570, ddc:615
الوصف: Metachromatic leukodystrophy (MLD) is a monogenic, autosomally recessively inherited lysosomal storage disease. Certain mutations of the arylsulfatase A (ASA) gene cause misfolding or absence of ASA. Physiologically ASA is responsible for the lysosomal degradation of 3-O-sulfogalactosylceramide (sulfatide), a main lipid component of myelin. Lack of ASA activity results in accumulation of sulfatide and consequently in demyelination processes, causing severe central nervous system pathology leading to premature death. Two therapeutic approaches for MLD were pursued in this thesis: enzyme replacement therapy (ERT) and chaperone therapy. For ERT recombinantly produced enzyme is injected intravenously. However, the blood brain barrier (BBB) prevents efficient transport into the brain, the main target of the disease. Therefore options to increase brain delivery were investigated. To this end ASA was bound to four different nanoparticle preparations that have been described to increase brain delivery of therapeutics. Inclusion during polymerization was unfeasible due to loss of ASA activity. Adsorption of ASA to the nanoparticle surface was efficient, however rapid and complete desorption was observed in presence of serum in vitro. In contrast, stable binding by direct crosslinking or high-affinity methods significantly reduced desorption in presence of serum. Two nanoparticle systems were thereon investigated with respect to their potential to increase brain delivery of ASA in vivo. However, contrary to the working hypothesis, brain delivery was not enhanced upon binding to nanoparticles in comparison to free ASA, although the overall biodistribution of ASA was altered. This was explained by rapid uptake via mannose 6-phosphate (M6P) receptor endocytosis. To reduce uptake by peripheral cells, a M6P binding domain was coupled to nanoparticles in order to physically shield ASA’s M6P residues that are recognized by M6P receptors on these cells. Indeed, in first in vitro experiments, shielding of ASA resulted in a ...
نوع الوثيقة: doctoral or postdoctoral thesis
وصف الملف: application/pdf
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/urn/urn:nbn:de:hbz:5n-38514; https://hdl.handle.net/20.500.11811/6213Test
الإتاحة: https://doi.org/20.500.11811/6213Test
https://hdl.handle.net/20.500.11811/6213Test
حقوق: In Copyright ; http://rightsstatements.org/vocab/InC/1.0Test/ ; openAccess
رقم الانضمام: edsbas.FF98B744
قاعدة البيانات: BASE